FTC OKs $76M Astellas-Maxygen Protein Program Deal
The Federal Trade Commission granted an early termination on Monday to the 30-day waiting period before Astellas Pharma Inc. can complete its $76 million purchase of all of Maxygen Inc.'s equity...To view the full article, register now.
Already a subscriber? Click here to view full article